記住我
In the published article, there was an error in Scheme 2 as published. The stereogenic center in compounds 9-11 was incorrectly depicted. The corrected Scheme 2 and its caption appear below.
Scheme 2. Sulfation of the pregnenolone (6) and pregnendiol (9) steroids.
In the published article, there was an error in Supplementary Data Sheet 1, section Compound characterisation. The name of the fourth compound was incorrectly captured as “Pregnanediol or (3S,8S,9S,10R,13S,14S,17S)-17-((S)-1-hydroxyethyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol (9).”
The correct name appears below:
“Pregnanediol or (3S,8S,9S,10R,13S,14S,17S)-17-((R)-1-hydroxyethyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol (9).”
In the published article, there was an error in Supplementary Data Sheet 1, section Compound characterisation. The name of the fifth compound was incorrectly captured as “Disodium-3,17-pregnanediol disulfate or sodium (S)-1-((3S,8S,9S,10R,13S,14S,17S)-10,13-dimethyl-3-(sulfonatooxy)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethyl sulfate (11).”
The correct name appears below:
“Disodium-3,17-pregnanediol disulfate or sodium (3S,8S,9S,10R,13S,14S,17S)-10,13-dimethyl-17-((R)-1-(sulfonatooxy)ethyl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl sulfate (11).”
The authors apologize for these errors and state that these do not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
留言 (0)